Skip to main content

Table 5 Relative risks (RRs) and heterogeneity tests for sensitivity analyses

From: Efficacy and safety of Si-Jun-Zi-Tang-based therapies for functional (non-ulcer) dyspepsia: a meta-analysis of randomized controlled trials

Excluded study

Pooled RR (95% CI)

Pheterogeneity; I2

Hu (2001) [32]

1.22 (1.13, 1.32)

0.03; 51%

Cao (2008) [33]

1.22 (1.13, 1.32)

0.03; 51%

Li (2008) [34]

1.23 (1.13, 1.33)

0.02; 52%

Deng and Su (2010)a [31]

1.23 (1.13, 1.34)

0.02; 52%

Deng and Su (2010)b [31]

1.24 (1.14, 1.35)

0.02; 52%

Mu (2012) [35]

1.21 (1.13, 1.31)

0.04; 48%

Zhang (2013) [36]

1.24 (1.17, 1.30)

0.38; 7%

Lv (2014) [37]

1.21 (1.13, 1.31)

0.04; 48%

Zhang (2014) [38]

1.19 (1.13, 1.27)

0.19; 27%

Lan and Yuan (2016) [39]

1.22 (1.13, 1.32)

0.02; 51%

Liu et al. (2016) [40]

1.23 (1.13, 1.33)

0.02; 52%

Li (2016) [41]

1.23 (1.14, 1.33)

0.02; 52%

  1. RR relative risk, CI confidence interval
  2. a high dosage; b low dosage